John L. Berk

John L. Berk

Auto-generated profile, based on publicly available information

John L. Berk

Boston University School of Medicine Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
FRFrederick L. Ruberg
Frederick L. Ruberg
JBJohn L. Berk
John L. Berk

25 December 2013 in JAMA
Verified
Journal Article
Open access
PDF file
JBJohn L. Berk
John L. Berk
OSOle B. Suhr
Ole B. Suhr
LOLaura Obici
Laura Obici
YSYoshiki Sekijima
Yoshiki Sekijima
SZSteven R. Zeldenrust
Steven R. Zeldenrust
FCfor the Diflunisal Trial Consortium
for the Diflunisal Trial Consortium
Hereditary transthyretin amyloidosis (ATTR) is a lethal, autosomal dominant genetic disease caused by the aggregation of variant and wild-type transthyretin (TTR), a thyroxine transport protein predominantly produced by the liver.1,2 More than 100 different mutations in the TTR gene destabilize its tetrameric structure, promoting TTR dissociation and misassembly into oligomeric aggregates including amyloid fibrils.3,4 The process of TTR amyloidogenesis produces a spectrum of debilitating disease ranging from pure polyneuropathy (transthyretin-type familial amyloid polyneuropathy [ATTR-FAP]) to selective heart involvement.5,6 In ATTR-FAP, small- and large-fiber injury induce sensory and autonomic deficits accompanied by motor weakness in a length-dependent fashion, mimicking manifestations of diabetic polyneuropathy. Untreated, patients exhibit progressive neurological deficits, dying 10 to 15 years after disease presentation.7 Fewer than 10 000 people are estimated to be clinically affected worldwide.8

1 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
YAYusuke Ando
Yusuke Ando
TCTeresa Coelho
Teresa Coelho
JBJohn L Berk
John L Berk
MCMárcia Waddington Cruz
Márcia Waddington Cruz
BEBo-Göran Ericzon
Bo-Göran Ericzon
FSFabrizio Salvi
Fabrizio Salvi
Transthyretin amyloidosis is a progressive and eventually fatal disease primarily characterized by sensory, motor, and autonomic neuropathy and/or cardiomyopathy. Given its phenotypic unpredictability and variability, transthyretin amyloidosis can be difficult to recognize and manage. Misdiagnosis is common, and patients may wait several years before accurate diagnosis, risking additional significant irreversible deterioration. This article aims to help physicians better understand transthyretin amyloidosis—and, specifically, familial amyloidotic polyneuropathy—so they can recognize and manage the disease more easily and discuss it with their patients. We provide guidance on making a definitive diagnosis, explain methods for disease staging and evaluation of disease progression, and discuss symptom mitigation and treatment strategies, including liver transplant and several pharmacotherapies that have shown promise in clinical trials.

20 January 2004 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MSMartha Skinner
Martha Skinner
VSVaishali Sanchorawala
Vaishali Sanchorawala
DSDavid C. Seldin
David C. Seldin
LDLaura M. Dember
Laura M. Dember
RFRodney H. Falk
Rodney H. Falk
DWDaniel G. Wright
Daniel G. Wright
AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective. To test survival and organ response in a large sample of patients treated with high-dose intravenous melphalan (100 to 200 mg/m2) and autologous blood stem-cell transplantation. 8-year longitudinal analysis of clinical effectiveness. University-affiliated specialty referral clinic. 701 consecutive new patients with AL amyloidosis. High-dose chemotherapy and autologous stem-cell transplantation for patients who met eligibility requirements based on organ involvement and clinical status. Survival analysis of all patients evaluated and a detailed analysis of treatment outcome in the subgroup that received high-dose melphalan and stem-cell transplantation. Among 701 patients with AL amyloidosis, 394 (56%) were eligible for high-dose melphalan and stem-cell transplantation; 82 did not proceed with treatment because of patient choice or disease progression. Median survival of the 312 patients who initiated treatment was 4.6 years. A complete hematologic response, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achieved in 40% of patients and was associated with prolonged survival. Statistically significant improvements occurred in end-organ disease and were greater in patients with a complete hematologic response. Mortality rate within 100 days of treatment with high-dose melphalan and stem-cell transplantation was 13%; patients with cardiomyopathy had the highest mortality rates. Treatment of selected patients with AL amyloidosis by using high-dose melphalan and stem-cell transplantation resulted in hematologic remission, improved 5-year survival, and reversal of amyloid-related disease in a substantial proportion.

23 July 2022 in Amyloid
Verified
Journal Article
Open access
DADavid Adams
David Adams
ITIvailo L. Tournev
Ivailo L. Tournev
MTMark S. Taylor
Mark S. Taylor
TCTeresa Coelho
Teresa Coelho
VPViolaine Planté-Bordeneuve
Violaine Planté-Bordeneuve
TCThe Helios-A Collaborators
The Helios-A Collaborators
The study objective was to assess the effect of vutrisiran, an RNA interference therapeutic that reduces transthyretin (TTR) production, in patients with hereditary transthyretin (ATTRv) amyloidosi...

4 September 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
OSOle B Suhr
Ole B Suhr
TCTeresa Coelho
Teresa Coelho
JBJuan Buades
Juan Buades
JPJean Pouget
Jean Pouget
ICIsabel Conceicao
Isabel Conceicao
DADavid Adams
David Adams
Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the transthyretin gene. This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with transthyretin-mediated familial amyloid polyneuropathy (FAP). In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the following doses: 0.01 (n = 4), 0.05 (n = 3), 0.15 (n = 3), or 0.3 (n = 7) mg/kg every 4 weeks (Q4W), or 0.3 mg/kg (n = 12) every 3 weeks (Q3W). Of 29 patients in the intent-to-treat population, 26 completed the study. Administration of patisiran led to rapid, dose-dependent, and durable knockdown of transthyretin, with the maximum effect seen with patisiran 0.3 mg/kg; levels of mutant and wild-type transthyretin were reduced to a similar extent in Val30Met patients. A mean level of knockdown exceeding 85 % after the second dose, with maximum knockdown of 96 %, was observed for the Q3W dose. The most common treatment-related adverse event (AE) was mild-to-moderate infusion-related reactions in 10.3 % of patients. Four serious AEs (SAEs) were reported in 1 patient administered 0.3 mg/kg Q3W (urinary tract infection, sepsis, nausea, vomiting), and 1 patient administered 0.3 mg/kg Q4W had 1 SAE (extravasation-related cellulitis). Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of transthyretin protein in patients with FAP. Patisiran 0.3 mg/kg Q3W is currently in phase III development. NCT01617967 .